Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib.
Saved in:
| Title: | Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib. |
|---|---|
| Authors: | Horinouchi, H.1 (AUTHOR), Cho, B.C.2 (AUTHOR), Camidge, D.R.3 (AUTHOR), Goto, K.4 (AUTHOR), Tomasini, P.5 (AUTHOR), Li, Y.6 (AUTHOR), Vasilopoulos, A.6 (AUTHOR), Brunsdon, P.6 (AUTHOR), Hoffman, D.6 (AUTHOR), Shi, W.6 (AUTHOR), Bolotin, E.6 (AUTHOR), Blot, V.6 (AUTHOR), Goldman, J.1,7 (AUTHOR) |
| Source: | Annals of Oncology. May2025, Vol. 36 Issue 5, p583-591. 9p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.01.001 |
